![]() It will also help ready the biotech’s earlier candidates for IND applications, which could come sometime in the next 12 to 18 months. It was led by Cambrian Biopharma and H&S Ventures, and will fund the Phase II development of SNS-301. The round, which the company is calling a Series AA, follows several seed rounds, Celebi said. “Right now we’re really focused on adding additional Phase II clinical and translational data to support SNS-301,” CEO John Celebi said. The Maryland-based biotech, formerly known as Panacea, is looking to expand Phase II trials for SNS-301, an engineered inactivated bacteriophage designed to “awaken” the immune system. Simply Wall St has no position in any stocks mentioned.Less than a month after offering a glimpse at early clinical data for its lead cancer immunotherapy at virtual ESMO, Sensei Biotherapeutics has reeled in $28.5 million to wade deeper into Phase II. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. We aim to bring you long-term focused analysis driven by fundamental data. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. This article by Simply Wall St is general in nature. Alternatively, email editorial-team (at). Have feedback on this article? Concerned about the content? Get in touch with us directly. We currently account for open market transactions and private dispositions, but not derivative transactions. So you may wish to see this free collection of high quality companies.įor the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. Of course Sensei Biotherapeutics may not be the best stock to buy. When we did our research, we found 4 warning signs for Sensei Biotherapeutics (2 shouldn't be ignored!) that we believe deserve your full attention. While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. Given that insiders also own a fair bit of Sensei Biotherapeutics we think they are probably pretty confident of a bright future. But on the other hand, the company made a loss during the last year, which makes us a little cautious. And an analysis of the transactions over the last year also gives us confidence. The recent insider purchases are heartening. What Might The Insider Transactions At Sensei Biotherapeutics Tell Us? We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders. Sensei Biotherapeutics insiders own about US$29m worth of shares. ![]() ![]() We usually like to see fairly high levels of insider ownership. Many investors like to check how much of a company is owned by insiders. Story continues Insider Ownership of Sensei Biotherapeutics Robert Pierce was the only individual insider to sell over the last year. So it may not tell us anything about how insiders feel about the current share price. The silver lining is that this sell-down took place above the latest price (US$5.24). While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. In the last twelve months, the biggest single sale by an insider was when the Chief R&D Officer, Robert Pierce, sold US$568k worth of shares at a price of US$7.13 per share. ![]() View our latest analysis for Sensei Biotherapeutics Sensei Biotherapeutics Insider Transactions Over The Last Year While insider transactions are not the most important thing when it comes to long-term investing, we do think it is perfectly logical to keep tabs on what insiders are doing. However, when multiple insiders purchase stock, like in Sensei Biotherapeutics, Inc.'s ( NASDAQ:SNSE) instance, it's good news for shareholders. When a single insider purchases stock, it is typically not a major deal.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |